ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0606

Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

April Jorge1, Baijun Zhou1, Yuqing Zhang2 and Hyon K. Choi3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital and Harvard Medical School, Lexington, MA

Meeting: ACR Convergence 2023

Keywords: comparative effectiveness, Damage Index, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0582–0608) SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when compared with prior ‘usual care.’ We sought to determine the risk of damage progression with belimumab versus alternative SLE immunosuppressants in a contemporary real world setting.

Methods: We identified all adults with SLE (defined by ≥2 ICD codes >30 days and < 2 years apart) in a United States multi-center electronic health record (EHR) database, TriNetX. We identified all patients who initiated belimumab, azathioprine (AZA), methotrexate (MTX), or mycophenolate (MMF) between 3/2011 and 8/2021. We designed and emulated a pragmatic target trial to compare the risk of damage progression with initiation of belimumab vs. AZA, belimumab vs. MTX, and belimumab vs MMF. For each comparison, eligible patients had never used the direct comparator but could have used other immunosuppressants and did not have lupus nephritis prior to the index date of treatment initiation. To emulate randomization, we used propensity score overlap weighting to balance baseline covariates, including demographics, geographic region, treatment initiation year, comorbidities including CKD, congestive heart failure, obesity, cardiovascular disease, the Charlson comorbidity index, tobacco use, SLE severity index (Garris C. J Med Econ 2013), SLE disease duration, baseline SLICC damage index score (categorized as 0, 1, or ≥2), medication use including glucocorticoids, hydroxychloroquine, and other immunosuppressants, and healthcare utilization. We assessed the outcome of damage progression defined by an increase in the SLICC damage index (SDI), which was adapted to administrative data using ICD codes. We conducted an intention-to-treat analysis and a per-protocol analysis using pooled logistic regression where we adjusted for adherence to assigned treatment with inverse probability of treatment weighting. We also assessed the mean change in the SDI at three years among patients with ≥3 years of follow-up using linear regression.

Results: We compared 2,434 and 5,644 initiators of belimumab and AZA, (Table 1), 2,163 and 7,224 initiators of belimumab and MTX, and 2,431 and 6,350 initiators of belimumab and MMF, respectively. In each comparison, covariates were balanced after propensity score overlap weighting. 95% were female; the mean age was 44 years. 53% had a baseline SDI of zero. After 5 years, over 41% in each treatment group developed ≥1 new damage item on the SDI. The risk of damage progression was lower with belimumab than mycophenolate (HR 0.74 [95% CI 0.67-0.83]; Table 2), but there was no difference in the risk of damage progression between belimumab and AZA or belimumab and MTX. Similarly, belimumab was associated with a lower 3-year change in SDI when compared with MMF, but there was no difference when compared with AZA and MTX (Table 3).

Conclusion: In this real world EHR-based SLE cohort, after accounting for baseline covariates associated with the risk of organ damage, belimumab was associated with a lower risk of damage progression than MMF but not AZA or MTX use. Limitations include the use of administrative claims to identify components of the SDI.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Jorge: None; B. Zhou: None; Y. Zhang: None; H. Choi: Ani, 2, Horizon, 2, 5, LG, 2, Protalix, 2, Shanton, 2.

To cite this abstract in AMA style:

Jorge A, Zhou B, Zhang Y, Choi H. Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/risk-of-damage-progression-with-belimumab-versus-oral-immunosuppressant-use-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-damage-progression-with-belimumab-versus-oral-immunosuppressant-use-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology